Insulin degludec (trade name: Tresiba) has been approved in Germany since January 2013 for the treatment of type 2 diabetes in adults. The drug is a long-acting insulin. It is used to control blood sugar levels for up to 24 hours.
Diabetes is a metabolic disease that affects many different parts of the body. In type 2 diabetes, the pancreas still produces enough insulin at first, but the body’s cells gradually lose the ability to absorb and use the insulin. If the blood sugar levels can't be lowered enough by diet changes and exercise, medications are used to regulate them.
Insulin degludec helps to prevent strong fluctuations in blood sugar levels and the problems caused by high and low blood sugar. It can also help to prevent the complications that may develop if blood sugar levels are too high.
Insulin degludec is injected once a day using an insulin pen. It is available in two different doses: 100 or 200 units per milliliter. For patients who haven't used insulin before, the recommended starting dose is 10 units per day. The dose is then adjusted individually, taking into account other blood-sugar reducing treatment, current blood sugar levels, and the target blood sugar levels.
For patients with type 2 diabetes, the treatment options include human insulin, if necessary together with other drugs such as metformin, empagliflozin or liraglutide.
In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of insulin degludec compared with the standard treatments for the following groups of people with type 2 diabetes:
- Adults who were unable to lower their blood sugar levels enough using at least two blood-sugar-lowering drugs (other than insulin).
- Adults who were unable to lower their blood sugar levels enough with insulin alone or together with additional blood-sugar-lowering drugs.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, G-BA passed a resolution on the added benefit of insulin degludec (Tresiba).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Insulin degludec (diabetes mellitus) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-84. February 27, 2019. (IQWiG reports; Volume 731).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.